All faculty are expected to disclose any real or apparent conflicts of
interest that may have a direct bearing on the subject matter of this continuing
education activity. Participants have the responsibility to assess the impact
(if any) of the disclosed information on the educational value of the activity.
All faculty have been offered a modest honorarium from the accredited provider
for their participation in this activity. The faculty have disclosed the
following information:
Bradley J. Monk, MD, FACOG, FACS, is Associate Professor, Division of
Gynecologic Oncology, University of California, Irvine, UCI Medical Center,
Orange, California. Dr Monk is on the speakers bureaus of sanofi-aventis,
GlaxoSmithKline, Eli Lilly and Co, Johnson & Johnson, MGI, MedImmune, Inc, and
Oncotech.
Robert L. Coleman, MD, FACOG, FACS, is Associate Professor, Department of
Gynecologic Oncology, University of Texas M. D. Anderson Cancer Center, Houston,
Texas. Dr Coleman is on the speakers bureaus of GlaxoSmithKline, Tibotec, and
Bristol-Myers Squibb.
Thomas J. Herzog, MD, FACOG, FACS, Director of the Division of Gynecologic
Oncology, Herbert Irving Pavilion, Columbia University, New York, New York. Dr Herzog receives grant/research support from Eli Lilly and Co, GlaxoSmithKline, sanofi-aventis, and Tibotec.
Anuja Jhingran, MD, is Associate Professor, Division of Radiation Oncology,
University of Texas M. D. Anderson Cancer Center, Houston, Texas. Dr Jhingran
has nothing to disclose.
Thomas C. Wright, MD, is Director of Obstetric and Gynecologic Pathology,
College of Physicians and Surgeons of Columbia University, New York, New York. Dr Wright has nothing to disclose.